Concepts (159)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 19 | 2017 | 412 | 2.120 |
Why?
|
| Brachytherapy | 10 | 2017 | 46 | 1.460 |
Why?
|
| Radiation Injuries | 3 | 2012 | 29 | 1.070 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 5 | 2017 | 52 | 0.930 |
Why?
|
| Radiotherapy, Conformal | 5 | 2011 | 20 | 0.910 |
Why?
|
| Skin | 2 | 2012 | 125 | 0.740 |
Why?
|
| Mastectomy, Segmental | 8 | 2009 | 29 | 0.660 |
Why?
|
| Radiotherapy Dosage | 14 | 2017 | 101 | 0.520 |
Why?
|
| Radiotherapy, Adjuvant | 5 | 2017 | 53 | 0.460 |
Why?
|
| Radiometry | 4 | 2017 | 25 | 0.450 |
Why?
|
| Carcinoma, Ductal, Breast | 4 | 2008 | 33 | 0.420 |
Why?
|
| Prone Position | 2 | 2011 | 32 | 0.410 |
Why?
|
| Thermal Conductivity | 1 | 2012 | 2 | 0.400 |
Why?
|
| Thermography | 1 | 2012 | 13 | 0.400 |
Why?
|
| Radiotherapy, Intensity-Modulated | 2 | 2009 | 36 | 0.390 |
Why?
|
| Lymph Nodes | 2 | 2011 | 73 | 0.380 |
Why?
|
| Breast | 3 | 2010 | 25 | 0.360 |
Why?
|
| Combined Modality Therapy | 12 | 2010 | 305 | 0.340 |
Why?
|
| Genital Neoplasms, Female | 1 | 2010 | 15 | 0.340 |
Why?
|
| Heart | 2 | 2009 | 62 | 0.340 |
Why?
|
| Axilla | 2 | 2008 | 14 | 0.330 |
Why?
|
| Female | 26 | 2012 | 15296 | 0.320 |
Why?
|
| Taxoids | 1 | 2009 | 11 | 0.320 |
Why?
|
| Radiodermatitis | 1 | 2009 | 4 | 0.320 |
Why?
|
| Antineoplastic Agents | 2 | 2009 | 202 | 0.300 |
Why?
|
| Middle Aged | 18 | 2011 | 9031 | 0.240 |
Why?
|
| Humans | 32 | 2017 | 27205 | 0.240 |
Why?
|
| Posture | 1 | 2003 | 63 | 0.210 |
Why?
|
| Adult | 17 | 2011 | 7916 | 0.190 |
Why?
|
| Head and Neck Neoplasms | 4 | 1997 | 147 | 0.190 |
Why?
|
| Carcinoma, Squamous Cell | 4 | 1997 | 172 | 0.190 |
Why?
|
| Aged | 15 | 2011 | 9076 | 0.180 |
Why?
|
| Feasibility Studies | 3 | 2011 | 221 | 0.180 |
Why?
|
| Intraoperative Care | 2 | 2017 | 42 | 0.160 |
Why?
|
| Lymph Node Excision | 2 | 1996 | 27 | 0.160 |
Why?
|
| Radiography | 4 | 2009 | 623 | 0.150 |
Why?
|
| Supine Position | 2 | 2011 | 21 | 0.150 |
Why?
|
| Mice | 2 | 2012 | 1413 | 0.140 |
Why?
|
| Treatment Failure | 2 | 2008 | 160 | 0.140 |
Why?
|
| Retrospective Studies | 7 | 2013 | 3566 | 0.130 |
Why?
|
| Lung | 3 | 2011 | 169 | 0.130 |
Why?
|
| Neoplasm Staging | 4 | 2010 | 368 | 0.130 |
Why?
|
| Animals | 2 | 2012 | 3645 | 0.110 |
Why?
|
| Imaging, Three-Dimensional | 2 | 2006 | 195 | 0.110 |
Why?
|
| Radiation Oncology | 1 | 2013 | 14 | 0.110 |
Why?
|
| Accreditation | 1 | 2013 | 15 | 0.110 |
Why?
|
| Pilot Projects | 3 | 2012 | 417 | 0.100 |
Why?
|
| Body Water | 1 | 2012 | 2 | 0.100 |
Why?
|
| Mice, Hairless | 1 | 2012 | 2 | 0.100 |
Why?
|
| Tomography | 1 | 2012 | 13 | 0.100 |
Why?
|
| Education, Medical, Graduate | 1 | 2013 | 79 | 0.100 |
Why?
|
| Fluorouracil | 5 | 1999 | 46 | 0.100 |
Why?
|
| Physicians | 1 | 2013 | 125 | 0.090 |
Why?
|
| Iridium Radioisotopes | 2 | 2008 | 3 | 0.090 |
Why?
|
| Logistic Models | 1 | 2012 | 399 | 0.090 |
Why?
|
| Monte Carlo Method | 2 | 2017 | 50 | 0.090 |
Why?
|
| Electronics | 2 | 2010 | 9 | 0.090 |
Why?
|
| Clinical Competence | 1 | 2013 | 210 | 0.090 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 6 | 1997 | 246 | 0.080 |
Why?
|
| Disease-Free Survival | 3 | 2007 | 180 | 0.080 |
Why?
|
| Internship and Residency | 1 | 2013 | 216 | 0.080 |
Why?
|
| Treatment Outcome | 6 | 2010 | 3542 | 0.080 |
Why?
|
| Radioisotope Teletherapy | 1 | 1989 | 1 | 0.080 |
Why?
|
| Neoplasm Recurrence, Local | 6 | 1996 | 220 | 0.080 |
Why?
|
| Contracture | 1 | 2009 | 12 | 0.080 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 1989 | 12 | 0.080 |
Why?
|
| Organ Size | 1 | 2009 | 95 | 0.080 |
Why?
|
| Cisplatin | 4 | 1997 | 61 | 0.080 |
Why?
|
| Biomarkers | 1 | 2012 | 558 | 0.080 |
Why?
|
| Liposarcoma | 1 | 1989 | 17 | 0.080 |
Why?
|
| Lymphatic Metastasis | 2 | 2008 | 93 | 0.080 |
Why?
|
| Heart Ventricles | 1 | 2009 | 92 | 0.080 |
Why?
|
| Thyroid Neoplasms | 1 | 1989 | 46 | 0.080 |
Why?
|
| Rectal Neoplasms | 1 | 1989 | 15 | 0.080 |
Why?
|
| Carcinoma, Lobular | 2 | 2007 | 23 | 0.080 |
Why?
|
| Follow-Up Studies | 7 | 2010 | 1803 | 0.080 |
Why?
|
| Models, Biological | 2 | 2004 | 320 | 0.070 |
Why?
|
| Carcinoma in Situ | 1 | 2007 | 10 | 0.070 |
Why?
|
| Mastectomy | 1 | 1987 | 36 | 0.070 |
Why?
|
| Aged, 80 and over | 5 | 2009 | 4826 | 0.070 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2007 | 694 | 0.070 |
Why?
|
| Cell Division | 2 | 1996 | 82 | 0.060 |
Why?
|
| Electrons | 1 | 2004 | 17 | 0.060 |
Why?
|
| Theophylline | 1 | 1983 | 2 | 0.050 |
Why?
|
| 1-Methyl-3-isobutylxanthine | 1 | 1983 | 6 | 0.050 |
Why?
|
| Radiation-Protective Agents | 1 | 1983 | 4 | 0.050 |
Why?
|
| Cyclic AMP | 1 | 1983 | 32 | 0.050 |
Why?
|
| Reference Values | 1 | 2003 | 185 | 0.050 |
Why?
|
| Chemotherapy, Adjuvant | 3 | 1996 | 84 | 0.050 |
Why?
|
| Time Factors | 4 | 1996 | 1448 | 0.040 |
Why?
|
| S Phase | 2 | 1996 | 11 | 0.040 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 1999 | 18 | 0.040 |
Why?
|
| Tongue Neoplasms | 1 | 1999 | 19 | 0.040 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 1999 | 35 | 0.040 |
Why?
|
| Carcinoma | 1 | 1999 | 68 | 0.040 |
Why?
|
| Antineoplastic Agents, Hormonal | 2 | 1996 | 19 | 0.040 |
Why?
|
| Tamoxifen | 2 | 1996 | 30 | 0.040 |
Why?
|
| Biopsy | 2 | 1996 | 200 | 0.040 |
Why?
|
| Neoplasm Invasiveness | 2 | 1995 | 94 | 0.040 |
Why?
|
| Water | 1 | 2017 | 29 | 0.040 |
Why?
|
| Dose-Response Relationship, Radiation | 2 | 2007 | 9 | 0.030 |
Why?
|
| Mouth Mucosa | 1 | 1996 | 13 | 0.030 |
Why?
|
| Paclitaxel | 1 | 1996 | 51 | 0.030 |
Why?
|
| Cell Count | 1 | 1996 | 81 | 0.030 |
Why?
|
| Cellulitis | 1 | 1996 | 10 | 0.030 |
Why?
|
| Esophageal Neoplasms | 1 | 1997 | 50 | 0.030 |
Why?
|
| Adenocarcinoma | 1 | 1997 | 140 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 1996 | 374 | 0.030 |
Why?
|
| Apoptosis | 1 | 1996 | 210 | 0.030 |
Why?
|
| Cell Cycle | 1 | 1995 | 34 | 0.030 |
Why?
|
| Male | 7 | 1999 | 14849 | 0.030 |
Why?
|
| Survival Rate | 1 | 1995 | 344 | 0.030 |
Why?
|
| Neoplasms, Second Primary | 1 | 1994 | 38 | 0.030 |
Why?
|
| Postoperative Care | 2 | 1996 | 135 | 0.030 |
Why?
|
| Age Factors | 1 | 1995 | 774 | 0.030 |
Why?
|
| Hodgkin Disease | 1 | 1993 | 19 | 0.030 |
Why?
|
| Safety | 1 | 2010 | 37 | 0.020 |
Why?
|
| Cobalt Radioisotopes | 1 | 1989 | 3 | 0.020 |
Why?
|
| Nasopharyngeal Neoplasms | 1 | 1989 | 3 | 0.020 |
Why?
|
| Anal Canal | 1 | 1989 | 3 | 0.020 |
Why?
|
| Child | 2 | 1993 | 1296 | 0.020 |
Why?
|
| Preoperative Care | 1 | 1989 | 119 | 0.020 |
Why?
|
| Statistics as Topic | 1 | 1987 | 103 | 0.020 |
Why?
|
| Random Allocation | 1 | 1987 | 123 | 0.020 |
Why?
|
| Hemibody Irradiation | 1 | 2007 | 2 | 0.020 |
Why?
|
| United States | 1 | 2013 | 2056 | 0.020 |
Why?
|
| Tumor Burden | 1 | 2007 | 28 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 1987 | 216 | 0.020 |
Why?
|
| Survival Analysis | 2 | 1997 | 260 | 0.020 |
Why?
|
| Equipment Design | 1 | 2006 | 139 | 0.020 |
Why?
|
| Relative Biological Effectiveness | 1 | 2004 | 5 | 0.010 |
Why?
|
| Particle Accelerators | 1 | 2004 | 5 | 0.010 |
Why?
|
| Body Burden | 1 | 2004 | 7 | 0.010 |
Why?
|
| Scattering, Radiation | 1 | 2004 | 33 | 0.010 |
Why?
|
| Models, Statistical | 1 | 2004 | 127 | 0.010 |
Why?
|
| Cell Survival | 1 | 1983 | 119 | 0.010 |
Why?
|
| Actuarial Analysis | 2 | 1995 | 8 | 0.010 |
Why?
|
| Cell Line | 1 | 1983 | 271 | 0.010 |
Why?
|
| Computer Simulation | 1 | 2004 | 194 | 0.010 |
Why?
|
| Risk Factors | 1 | 1989 | 2330 | 0.010 |
Why?
|
| Heart Diseases | 1 | 1999 | 62 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 1997 | 52 | 0.010 |
Why?
|
| Esophagectomy | 1 | 1997 | 23 | 0.010 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 1996 | 12 | 0.010 |
Why?
|
| Anti-Inflammatory Agents | 1 | 1996 | 77 | 0.010 |
Why?
|
| Idoxuridine | 1 | 1995 | 2 | 0.010 |
Why?
|
| Mitotic Index | 1 | 1995 | 6 | 0.010 |
Why?
|
| G2 Phase | 1 | 1995 | 5 | 0.010 |
Why?
|
| Bromodeoxyuridine | 1 | 1995 | 10 | 0.010 |
Why?
|
| DNA, Neoplasm | 1 | 1995 | 24 | 0.010 |
Why?
|
| Recurrence | 1 | 1996 | 313 | 0.010 |
Why?
|
| Lymphoma | 1 | 1995 | 36 | 0.010 |
Why?
|
| Regression Analysis | 1 | 1995 | 259 | 0.010 |
Why?
|
| Kinetics | 1 | 1995 | 180 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 1995 | 350 | 0.010 |
Why?
|
| Contraindications | 1 | 1994 | 31 | 0.010 |
Why?
|
| Anti-Bacterial Agents | 1 | 1996 | 370 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 1996 | 928 | 0.010 |
Why?
|
| Adolescent | 1 | 1993 | 2196 | 0.000 |
Why?
|